NewAmsterdam Pharma Co N.V. (NAMS)
Data as of , from SEC Form 4 filings.
See up to 3 months of NAMS. The 7-day demo opens the 1M and 3M ranges and puts NAMS on your watchlist.
Start 7-day demoLatest NAMS insider trades
About NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
- NARRDEN, P7
- 100
- 2022
- XNAS
https://www.newamsterdampharma.comSEC filings for NAMS on EDGAR
NAMS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 10,000 | $227K |
| Open-market sale | 6 | 281,846 | $7.85M |
| Grant or award | 2 | 17,200 | |
NAMS insider transactions (Form 4)
5451 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Louise Frederika Kooij - Officer | Option exercise | Ordinary Shares | 150,000 | $10.00 | $1.50M | |
| Louise Frederika Kooij - Officer | Open-market sale | Ordinary Shares | 53,104 | $25.31 | $1.34M | |
| Louise Frederika Kooij - Officer | Open-market sale | Ordinary Shares | 96,896 | $26.11 | $2.53M | |
| Louise Frederika Kooij - Officer | Option exercise | Option (right to buy) | 150,000 | $0.00 | - | |
| Louise Frederika Kooij - Officer | Open-market sale | Ordinary Shares | 18,073 | $25.09 | $453K | |
| Louise Frederika Kooij - Officer | Option exercise | Ordinary Shares | 18,073 | - | - | |
| Louise Frederika Kooij - Officer | Option exercise | Option (right to buy) | 18,073 | $0.00 | - | |
| Louise Frederika Kooij - Officer | Open-market sale | Ordinary Shares | 8,269 | $24.86 | $206K | |
| Johannes Jacob Pieter Kastelein - Officer | Open-market sale | Ordinary Shares | 50,000 | $24.29 | $1.21M | |
| Johannes Jacob Pieter Kastelein - Officer | Open-market sale | Ordinary Shares | 42,342 | $25.08 | $1.06M | |
| Johannes Jacob Pieter Kastelein - Officer | Open-market sale | Ordinary Shares | 7,658 | $25.49 | $195K | |
 James N. Topper | Open-market purchase | Ordinary Shares | 471 | $23.98 | $11K | |
| Douglas F. Kling - Officer | Option exercise | Ordinary Shares | 47,569 | $10.90 | $519K | |
| Douglas F. Kling - Officer | Open-market sale | Ordinary Shares | 44,025 | $21.38 | $941K | |
| Douglas F. Kling - Officer | Open-market sale | Ordinary Shares | 3,544 | $22.12 | $78K | |
| Douglas F. Kling - Officer | Option exercise | Ordinary Shares | 51,043 | $10.90 | $556K | |
| Douglas F. Kling - Officer | Open-market sale | Ordinary Shares | 51,043 | $21.10 | $1.08M | |
| Douglas F. Kling - Officer | Option exercise | Option (right to buy) | 47,569 | $0.00 | - | |
| Douglas F. Kling - Officer | Option exercise | Option (right to buy) | 51,043 | $0.00 | - | |
| Louis G. Lange | Option exercise | Ordinary Shares | 68 | $0.00 | - | |
| Louis G. Lange | Option exercise | Restricted Stock Unit | 68 | - | - | |
| Louis G. Lange | Option exercise | Ordinary Shares | 69 | $0.00 | - | |
| Louis G. Lange | Option exercise | Restricted Stock Unit | 69 | - | - | |
| Louis G. Lange | Option exercise | Ordinary Shares | 69 | $0.00 | - | |
| Louis G. Lange | Option exercise | Restricted Stock Unit | 69 | - | - | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 33,438 | $26.01 | $870K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 41,472 | $25.95 | $1.08M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 44,143 | $25.53 | $1.13M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 5,629 | $26.13 | $147K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 25,132 | $25.49 | $641K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 16,164 | $25.66 | $415K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 54,518 | $25.72 | $1.40M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 46,210 | $26.55 | $1.23M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 56,506 | $25.45 | $1.44M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 1,096 | $25.00 | $27K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 66,648 | $25.60 | $1.71M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 47,736 | $26.45 | $1.26M | |
| Bain Capital Life Sciences Investors, LLC | Open-market purchase | Pre-Funded Warrant (right to buy) | 1,632,653 | $24.50 | $40.00M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 140,048 | $25.25 | $3.54M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 25,963 | $26.18 | $680K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 25,751 | $25.01 | $644K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 259,739 | $25.22 | $6.55M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 48,511 | $26.15 | $1.27M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 130,561 | $25.26 | $3.30M | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 18,583 | $26.41 | $491K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 4,894 | $27.11 | $133K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 8,530 | $25.02 | $213K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 33,273 | $25.08 | $834K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 1,066 | $25.00 | $27K | |
| ForGrowth NAP B.V. | Open-market sale | Ordinary Shares | 9,832 | $25.01 | $246K | |
| Michael H. Davidson - Officer | Gift | Warrant (right to buy) | 15,000 | $11.50 | $173K | |
| Louise Frederika Kooij - Officer | Option exercise | Ordinary Shares | 45,000 | - | - | |
| Louise Frederika Kooij - Officer | Open-market sale | Ordinary Shares | 45,000 | $15.72 | $707K | |
| Louise Frederika Kooij - Officer | Option exercise | Option (right to buy) | 45,000 | $0.00 | - |
Recent NAMS Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Kastelein Johannes Jacob Pieter | Affiliate | 250,000 | $6.97M | View on EDGAR | |
| Kastelein Johannes Jacob Pieter | Affiliate | 125,000 |
NAMS insider trading FAQ
What is the latest insider trade for NAMS?
NewAmsterdam Pharma Co N.V. (NAMS) had 6 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for NAMS runs to 51 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NAMS stock?
1 insider purchase of NAMS was filed in the last 90 days, totaling $226K.
How many insiders are selling NAMS stock?
6 insider sales of NAMS were filed in the last 90 days, totaling $7.85M.
Where can I see NAMS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NAMS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Johannes Jacob Pieter Kastelein view on EDGAR
- - Michael H. Davidson view on EDGAR
- - John W. Smither view on EDGAR
- - Robert William Gunning view on EDGAR
- - Johannes Jacob Pieter Kastelein view on EDGAR
- - Louise Frederika Kooij view on EDGAR
- - Louise Frederika Kooij view on EDGAR
- - Louise Frederika Kooij view on EDGAR
- - Louis G. Lange view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where NAMS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NAMS with a 7-day demo
- NAMS on your watchlist
- Every NAMS Form 4 filing on record
- Up to 3 months of NAMS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
